Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023418 (
leukemia
)
93,477
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The Mixed Lineage
Leukemia
(MLL) gene is commonly involved in translocations in infantile
leukemia
and is amplified in some cases of adult myeloid leukemia. A homolog of MLL denoted MLL2, which represents the second human homolog of the Drosophila trithorax gene, was characterized by assembling ESTs, the KIAA0304 cDNA clone, RT - PCR fragments and a new clone isolated from a cDNA phage library and compared to the available genomic sequence. The MLL2 gene maps to 19q13.1, a region of frequent rearrangement or amplification in solid tumors. MLL2 consists of an 8.5 - 9 kb transcript and spans 20 kb of genomic DNA. The predicted
MLL2 protein
possesses all of the major domains defined in MLL and the two genes have a similar genomic structure. We find that MLL2 is amplified in two of 14 pancreatic carcinoma cell lines and one of five glioblastoma cell lines and is a likely critical gene in 19q13.1 amplifications. It is also a candidate for chromosomal rearrangements involving this chromosome locus. MLL2 is one additional mammalian trithorax-group gene with involvement in human cancer.
...
PMID:MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines. 1063 8
Kabuki syndrome (also known as Niikawa-Kuroki syndrome) is a rare autosomal disorder, characterized by an unusual face, short stature, skeletal, visceral and dermatoglyphic abnormalities, cardiac anomalies, mental retardation, and immunological defects. Point mutations and large intragenic deletions and duplications of the mixed lineage
leukemia
2 (MLL2) and exons deletions of lysine demethylase 6A (-KDM6A) genes have been identified as its underlying causes. We report on the first description of a Moroccan Kabuki syndrome patient with typical facial features, developmental delay, finger pads, and other anomalies carrying a novel splice site mutation in the MLL2 gene that produces a truncated and likely pathogenetic form of
MLL2 protein
.
...
PMID:Report of the First Clinical Case of a Moroccan Kabuki Patient with a Novel MLL2 Mutation. 2365 88
Mixed linage
leukemia
gene 2 (MLL2) is identified as a novel mutation gene in diffuse large B cell lymphoma (DLBCL). However, the significance of
MLL2 protein
expression for the prognosis of DLBCL is unclear. In this study, we detected
MLL2 protein
expression in primary gastrointestinal diffuse large B cell lymphoma (PGI-DLBCL) samples by using tissue microarray immunohistochemistry, and analyzed the correlation between
MLL2 protein
expression and tumor proliferation activity. In addition, we investigated clinical significance of
MLL2 protein
expression for PGI-DLBCL prognosis. We found that there was significant difference in
MLL2 protein
expression between PGI-DLBCL and reactive hyperplasia of lymph node. High expression of
MLL2 protein
indicated higher clinical stage. In older patients (>60 years) with PGI-DLBCL,
MLL2 protein
expression was positively correlated with Ki-67 expression and negatively correlated with patient survival. Our data suggest that
MLL2 protein
is overexpressed in PGI-DLBCL and appears as a prognostic factor for patients of PGI-DLBCL, especially for those older than 60 years old.
...
PMID:MLL2 protein is a prognostic marker for gastrointestinal diffuse large B-cell lymphoma. 2672 99